This HTML5 document contains 29 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n14http://linked.opendata.cz/resource/drugbank/drug/DB00056/identifier/wikipedia/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00056/identifier/pharmgkb/
n7http://linked.opendata.cz/resource/drugbank/company/
n11http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n12http://bio2rdf.org/drugbank:
n15http://linked.opendata.cz/resource/drugbank/drug/DB00056/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n16http://linked.opendata.cz/resource/drugbank/drug/DB00056/identifier/national-drug-code-directory/
n18http://linked.opendata.cz/resource/drugbank/patent/
n9http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n20http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n10http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n19http://www.drugs.com/cdi/
n21http://linked.opendata.cz/resource/drugbank/property/
n5http://www.rxlist.com/cgi/generic2/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB00056
rdf:type
n3:Drug
n3:description
Recombinant humanized IgG4, kappa antibody conjugated with a cytotoxic antitumor antibiotic, calicheamicin, isolated from fermentation of a bacterium, Micromonospora echinospora ssp. calichensis. The antibody portion of Mylotarg binds specifically to the CD33 antigen, The anti-CD33 hP67.6 antibody is produced by mammalian cell suspension culture using a myeloma NS0 cell line. Gemtuzumab ozogamicin (trade name Mylotarg) was withdrawn in 2010 when a clinical trial showed the drug increased patient death and exhibited no advantages over traditional cancer therapies.
n3:generalReferences
# Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R: Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001 Jun;7(6):1490-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11410481 # Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, Estey EH: Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001 Jul 15;92(2):406-13. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11466696 # Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, Alyea EP, Antin JH, Stone RM, Soiffer RJ, DeAngelo DJ: Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003 Sep 1;102(5):1578-82. Epub 2003 May 8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12738663
n3:group
approved investigational withdrawn
n3:indication
For treatment of CD33-positive acute myeloid leukemia in patients 60 and over who are not candidates for other chemotherapy.
n3:manufacturer
n7:271B4273-363D-11E5-9242-09173F13E4C5
owl:sameAs
n9:DB00056 n12:DB00056
dcterms:title
Gemtuzumab ozogamicin
adms:identifier
n14:Gemtuzumab_ozogamicin n15:DB00056 n16:0008-4510-01 n17:PA164749431
n3:mechanismOfAction
Mylotarg is directed against the CD33 antigen expressed by hematopoietic cells. Binding of the anti-CD33 antibody portion of Mylotarg with the CD33 antigen results in the formation of a complex that is internalized. Upon internalization, the calicheamicin derivative is released inside the lysosomes of the myeloid cell. The released calicheamicin derivative binds to DNA in the minor groove resulting in DNA double strand breaks and cell death.
n3:packager
n7:271B4271-363D-11E5-9242-09173F13E4C5 n7:271B4272-363D-11E5-9242-09173F13E4C5
n3:patent
n18:5773001 n18:5585089
n3:toxicity
The most frequently reported toxicities are myelosuppression and hepatic veno-occlusive disorder.
n10:hasConcept
n11:M0483090
foaf:page
n5:gemtuzumab.htm n19:gemtuzumab-ozogamicin.html
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
220578-59-6
n3:category
n3:containedIn
n20:271B4274-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n21:271B4275-363D-11E5-9242-09173F13E4C5